Palvella Therapeutics PVLA Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's financing cash flow?
- Palvella Therapeutics (PVLA) reported financing cash flow of $214.73M in Q1 2026.
- How has Palvella Therapeutics's financing cash flow changed year-over-year?
- Palvella Therapeutics's financing cash flow increased by 17964.5% year-over-year, from -$1.2M to $214.73M.
- What is the long-term trend for Palvella Therapeutics's financing cash flow?
- Over 2 years (2021 to 2024), Palvella Therapeutics's financing cash flow has grown at a 21.4% compound annual growth rate (CAGR), from $59.13M to $87.09M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.